GlassScriptPhysician profile
Emily Ramsey
NPI 1023745973
$1,753.84
in general payments reported to CMS, 2019-2025
29 companies · $520 in 2025
The $520 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $499 · 2023: $471 · 2024: $264 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.76 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.92 | 2022-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $121.12 | 2024-2025 | Calquence, Lynparza |
| Janssen Biotech, INC. | $112.94 | 2022-2025 | Carvykti, Rybrevant, Stelara |
| Daiichi Sankyo INC. | $100.62 | 2024-2025 | Enhertu, Vanflyta |
| Genzyme Corporation | $100.08 | 2022-2023 | |
| Pfizer INC. | $99.57 | 2023-2025 | |
| Gilead Sciences, INC. | $64.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $62.61 | 2024-2025 | |
| Sobi, INC | $59.12 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $45.59 | 2025 | Keytruda, Welireg |
| Intercept Pharmaceuticals, INC. | $45.41 | 2022-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $45.24 | 2022-2023 | Entyvio |
| Evoke Pharma, INC. | $43.79 | 2022-2023 | Gimoti |
| Csl Behring | $39.26 | 2022-2023 | Kcentra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $38.49 | 2023 | Imbruvica |
| Pharmaessentia USA Corporation | $37.92 | 2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $35.92 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $21.65 | 2022 | |
| Boston Scientific Corporation | $19.82 | 2022 | |
| Iovance Biotherapeutics, INC. | $19.47 | 2025 | Amtagvi |
| Eisai INC. | $17.79 | 2025 | |
| Aveo Pharmaceuticals, INC. | $17.74 | 2024 | |
| Deciphera Pharmaceuticals INC. | $16.79 | 2025 | Romvimza, Qinlock |
| Rigel Pharmaceuticals, INC. | $14.68 | 2024 | Rezlidhia, Tavalisse |
| Lantheus Medical Imaging, INC. | $14.62 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.40 | 2023 | |
| Beigene USA, INC. | $13.51 | 2024 | Tevimbra |
| Jazz Pharmaceuticals INC. | $13.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.